GRI Bio (NASDAQ: GRI) is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis.

Multimeric Biotherapeutics is an R&D biotechnology company developing its FortiVac vaccine platform technology to generate robust CD8+ T cell responses.

Bird Rock Biotech provides services for the life sciences industry. Bird Rock Biotech focuses on biotech R&D, business development and executive leadership and primarily provides services to the investment community and earlier stage start-up companies. Bird Rock Biotech has helped launch two companies; Multimeric Biotherapeutics, Inc. (2008) and Glycoregimmune, Inc. (2009); has advised several additional startup technology companies, and has provided technical due diligence to private investment groups for multiple opportunities.

Pharmexa Inc is a US-subsidiary of Pharmexa A/S [CSE:PHARMX] is a recognized world-leader in T cell epitope identification and the development of polyepitope vaccines for infectious disease and cancer.

Pharmexa A/S [CSE: PHARMX] is a danish biotechnology company developing therapeutic vaccines for cancer, autoimmunity and other life-threatening diseases.